Retained Earnings (Accumulated Deficit) of VBI Vaccines Inc/BC from 31 Dec 2015 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
VBI Vaccines Inc/BC quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2015 to 31 Mar 2024.
  • VBI Vaccines Inc/BC Retained Earnings (Accumulated Deficit) for the quarter ending 31 Mar 2024 was $600,345,000, a 16% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

VBI Vaccines Inc/BC Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $600,345,000 -$82,985,000 -16% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $582,445,000 -$92,836,000 -19% 31 Dec 2023 10-Q 15 May 2024 2024 Q1
Q3 2023 $582,432,000 -$113,964,000 -24% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $561,988,000 -$118,729,000 -27% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $517,360,000 -$119,800,000 -30% 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $489,609,000 -$111,238,000 -29% 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $468,468,000 -$108,880,000 -30% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $443,259,000 -$99,518,000 -29% 30 Jun 2022 10-Q 08 Aug 2022 2022 Q2
Q1 2022 $397,560,000 -$71,295,000 -22% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $378,371,000 -$69,753,000 -23% 31 Dec 2021 10-K 13 Mar 2023 2022 FY
Q3 2021 $359,588,000 -$66,332,000 -23% 30 Sep 2021 10-Q 08 Nov 2021 2021 Q3
Q2 2021 $343,741,000 -$63,482,000 -23% 30 Jun 2021 10-Q 02 Aug 2021 2021 Q2
Q1 2021 $326,265,000 -$55,519,000 -21% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $308,618,000 -$46,230,000 -18% 31 Dec 2020 10-K 07 Mar 2022 2021 FY
Q3 2020 $293,256,000 -$41,743,000 -17% 30 Sep 2020 10-Q 02 Nov 2020 2020 Q3
Q2 2020 $280,259,000 -$44,908,000 -19% 30 Jun 2020 10-Q 31 Jul 2020 2020 Q2
Q1 2020 $270,746,000 -$48,565,000 -22% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $262,388,000 -$54,813,000 -26% 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q3 2019 $251,513,000 -$63,188,000 -34% 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 $235,351,000 -$62,394,000 -36% 30 Jun 2019 10-Q 09 Aug 2019 2019 Q2
Q1 2019 $222,181,000 -$65,955,000 -42% 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $207,575,000 -$63,600,000 -44% 31 Dec 2018 10-K 05 Mar 2020 2019 FY
Q3 2018 $188,325,000 -$55,893,000 -42% 30 Sep 2018 10-Q 09 Nov 2018 2018 Q3
Q2 2018 $172,957,000 -$50,326,000 -41% 30 Jun 2018 10-Q 26 Jul 2018 2018 Q2
Q1 2018 $156,226,000 -$42,608,000 -38% 31 Mar 2018 10-Q 01 May 2018 2018 Q1
Q4 2017 $143,975,000 -$38,995,000 -37% 31 Dec 2017 10-K 25 Feb 2019 2018 FY
Q3 2017 $132,432,000 30 Sep 2017 10-Q 13 Nov 2017 2017 Q3
Q2 2017 $122,631,000 30 Jun 2017 10-Q 31 Jul 2017 2017 Q2
Q1 2017 $113,618,000 31 Mar 2017 10-Q 15 May 2017 2017 Q1
Q4 2016 $104,980,000 -$23,205,000 -28% 31 Dec 2016 10-K 26 Feb 2018 2017 FY
Q4 2015 $81,775,000 31 Dec 2015 10-K 20 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.